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Summary The soluble ectodomain of c-erbB-2 oncoprotein was measured using a sandwich enzyme immunoassay in serafrom 184 patients
with renal cell carcinoma before initiation of treatment. The median serum level was 2062 U ml-' (range 865-4905 U ml-'). Levels were
unaffected by sex, age and renal function. An inverse relation between disease stage (P = 0.0017) and tumour grade (P = 0.0009) and the
serum level of c-erbB-2 ectodomain was observed. Survival time for patients with serum levels above median level was significantly longer
than for patients with lower levels (P = 0.003). In a multivariate analysis, c-erbB-2 oncoprotein lost its prognostic information, while tumour
stage and tumour grade were identified as independent prognostic factors.
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The c-erbB-2 proto-oncogene, also named HER-2/neu, is situated
on chromosome 17 and encodes a transmembrane protein of
185 kDa (Schechter et al, 1985). This protein demonstrates struc-
tural similarities with the epidermal growth factor (EGF) receptor,
with an extracellular glycosylated domain, a transmembrane
domain and an intracellular domain with tyrosine kinase activity
(Coussens et al, 1985). Amplification and overexpression of
c-erbB-2 has been reported in different types of malignant
tumours (Yokota et al, 1986; Venter et al, 1987) and especially in
breast and ovarian cancer, oncogene overexpression may predict
prognosis (Slamon et al, 1987, 1989; Tandon et al, 1989).
In renal cell carcinoma, the expression of c-erbB-2 has been
analysed, and Yokota et al (1986) demonstrated amplification in
one of four tumours using Southern blot hybridization. Yao et al
(1988), however, found no expression using Northern blot
analysis. Using the same method, Freeman et al (1989), Weidneret
al (1990) and Rotter et al (1992) all found lower expression of
c-erbB-2 mRNA in tumour tissue than in non-neoplastic kidney
tissue, while Stumm et al (1996) found frequent overexpression of
erbB-2 mRNA using in situ hybridization. Herrera (1991) demon-
strated overexpression of c-erbB-2 in paraffin-embedded tumours
using immunocytochemistry, and Stumm et al (1996) found high
levels in 22 of34 fresh-frozen tumours.
In human breast cancer cell lines, the extracellular domain of
c-erbB-2protein is shedfromthesurface (Mori etal, 1990; Zabrecky
et al, 1991), and the soluble protein fragment can be quantified by
means of immunological methods (McKenzie et al, 1989). Serum
levels ofthis ectodomain have been analysed mostly in breast cancer
patients (Mori etal, 1990; Cameyetal, 1991; Leitzel etal, 1992), and
Kandl et al (1994) have demonstrated its prognostic value.
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The aim ofthe present study was to evaluate the serum levels of
the soluble ectodomain of c-erbB-2 oncoprotein in renal cell
carcinoma in relation to clinicopathological parameters and to the
clinical course ofdisease.
MATERIALS AND METHODS
Patients
One hundred and eighty-four patients with histologically verified
renal cell carcinoma were included in the study. The patients were
admitted to the Department of Urology, University Hospital in
Umea, from 1982 to 1994. There were 112 male and 72 female
patients, and their median age was 66 years (range 25-85 years).
The patients had a clinical examination including chest radio-
graphy, computerized tomography or ultrasonography of the
abdomen. In case of symptoms, bone scintigraphy was performed.
One hundred and seventy-three patients were operated with radical
nephrectomy, three with partial resection and eight patients had
palliative treatments with medroxyprogesterone, arterial occlusion
or interferon because of advanced disease. The patients were
staged according to Robson et al (1969), and tumour grade was
assessed according to Skinner et al (1971) on a four-grade scale.
Tumour size was measured on the surgical specimen or by
computerized tomography. During the study, 93 patients died of
renal cell carcinoma and 23 ofintercurrentdiseases. At the time of
follow-up, 68 patients were alive, three with verified tumour
relapse. The median follow-up time of these patients was 65
months (range 3-149 months). Sera from 23 patients with renal
cysts were analysed and used as clinical control.
C-erbB-2 analysis
Serumsamples weretakenafterpatients' informedconsentandbefore
initiation of therapy and stored at -80°C. C-erbB-2 was analysed in
duplicate using a commercial enzyme-linked immunosorbent assay
neuAssay (QIA 10) fromOncogene Science, Uniondale, NY, USA.
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Table 1 Soluble ectodomain of c-erbB-2 oncoprotein in relation to disease
stage and tumour grade
No. of patients c-erbB-2 (U ml-') P-value'
Mean s.d. median
Stage
71 2339 603 2265
II 8 1973 583 2075 001
III 42 2082 676 1965 0.0017
IV 63 2089 717 1930
Grade
1 4 2383 498 2482
2 41 2337 588 2265
3 93 2160 581 2070 0.0009
4 46 2058 869 1865
aJonckheere-Terpstra test. s.d., standard deviation.
Statistics
For statistical calculations the Mann-Whitney, the Jonckheere-
Terpstra and Fisher's exact tests were used (Sprent, 1989). Survival
analyses were performed according to the Kaplan-Meier method
using the log-rank test. Multivariate analysis ofprognostic factors
were performed according to Cox's proportional hazard model.
RESULTS
The soluble ectodomain of c-erbB-2 oncoprotein was assessed in
serum from 184 patients with renal cell carcinoma. The median
value, 2062 U ml-' (range 865-4905 U ml-'), was significantly
lower than that of 23 patients with renal cysts (median 2524; P =
0.0014). After subdivision according to disease stages (Table 1), a
significant inverse relation between ectodomain level and stage
was observed (P = 0.0017, Jonckheere-Terpstra test). A similar
inverse relation was observed between serum levels and tumour
grade (P = 0.0009). The yearly variation from 1982-94 was
analysed, and no trend towards increase or decrease of the levels
were found, indicating that the soluble ectodomain was stable
during storage (data not shown).
No difference between the levels in male orfemale patients was
observed. Nor was there any significant difference when the
patients were subdivided according to age or renal function
assessed as serum creatinine, as shown in Table 2.
Survival time was compared between patients with c-erbB-2
above and below the median value (2060 U 1-l), as shown in the
Figure. Prognosis was significantly better for patients with higher
levels than for those with lower levels (P = 0.003, log-rank test).
When survival was analysed in different disease stages separately,
the same tendency was observed in stage I disease (P = 0.047).
Patients with c-erbB-2 above median had a significantly higher
survival rate and longer survival time when compared with those
with lower concentrations. For patients with stage II-III and stage
IV disease no such difference could be observed. No difference
in age or gender ratio was found when all patients with
c-erbB-2 levels above median were compared with those with c-
erbB-2 levels below median. There was, however, significant
differences in disease stage, tumour diameter and outcome as
shown in Table 2.
Table 2 Comparison of patients with different levels of soluble ectodomain of
c-erbB-2 oncoprotein
c-erbB-2 (U ml-') P-value'
< 2060 > 2060
Number of patients 92 92
Age (years) 65± 11.8 63± 11.3 NS
(mean ± s.d.)
Male/female 57/35 55/37 NS
Serum creatinine 100 ± 44 96 ± 35 NS
(mean ± s.d.)
Stage
l-ll 31 48 0.017
III-IV 61 44
Grade
1-2 17 28 0.086
3-4 75 64
Turnour diameter (mm)
(mean ± s.d.) 88 ± 36 70 ± 28 0.0013
Survival (number)
Dead of RCC 56 39 0.0038
Alive 23 43
Dead (other causes) 13 10
aFisher's exact and Mann-Whitney tests. s.d., standard deviation; NS, not
significant; RCC, renal cell carcinoma.
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Figure Survival according to the Kaplan-Meier method of 92 patients with
soluble ectodomain of c-erbB-2 oncoprotein . 2060 U ml-' (-) and of 92
patients with levels < 2060 U ml-1 (- - -)
Multivariate analysis
The prognostic value of age, gender, disease stage, tumour grade
and soluble ectodomain of c-erbB-2 protein level was assessed
in a multivariate analysis using the Cox method. As shown in
Table 3, disease stage and tumour grade were independent predic-
tors ofprognosis.
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Table 3 Multivariate analysis of prognostic factors in 184 patients with renal
cell carcinoma
Prognostic factor Risk estimate P-value 95% confidence Interval
Lower Upper
Age (years)
<65 1.0
265 1.0 0.96 0.67 1.52
Gender
Male 1.0
Female 1.0 0.84 0.68 1.60
Stage
l-ll 1.0
III-IV 13.5 < 0.001 6.30 28.82
Grade
1-2 1.0
3-4 2.7 0.027 1.12 6.44
c-erbB-2 (U ml-')
<2060 1.0
* 2060 0.8 0.32 0.52 1.24
DISCUSSION
In the present study the extracellular domain ofthe c-erbB-2 onco-
protein in serafrompatients withrenal cell carcinomawas analysed.
The c-erbB-2 oncogene product is areceptor-like structure homolo-
gous to the EGF receptor. Press et al (1990) identified this oncopro-
tein immunohistochemically on the membranes of most normal
epithelial cells - stronger in human fetal tissues, weaker in adult
tissues. The oncogene product is hence expressed on the normal cell
membrane andis probably involved in cell proliferation.
The c-erbB-2 oncogene has beenextensively evaluated in breast
cancer, in which about 30% of the tumours show overexpression
(Lupu et al, 1995). In renal cell carcinomas, on the other hand, the
c-erbB-2 oncogene has only been analysed in a limited number of
tumours. Yokota et al (1986) found gene amplification in one of
four renal cell carcinomas using Southern blot analysis, while
Freeman et al (1989), Weidner etal (1990) and Stumm et al (1996)
were unable to detect any amplification ofthe c-erbB-2 oncogene.
The transcript of the c-erbB-2 oncogene has been analysed
using Northern blot analysis in renal cell carcinoma by Yao et al
(1988), who found no expression in 16 tumours. Weidner et al
(1990) and Rotter et al (1992) found lower mRNA expression in
tumour than in normal renal tissue. Freeman et al (1989) also
found lower mRNA expression in tumour than in normal renal
tissueusing dot blot analysis, while Stumm et al (1996) foundhigh
or moderate expression in 29 of 34 tumours using in situ
hybridization. Weidner et al (1990) related the results of the
Northern blot analysis with tumour grade and were unable to find
any correlation. Rotter et al (1992), however, found a non-signifi-
cant inverse relation between the c-erbB-2 oncoprotein level and
tumourgrade. Taken together, these results indicate thatamplifica-
tion of the c-erbB-2 oncogene is a rare event in renal cell carci-
noma. mRNA expression assessed with different methods seems
to be variable, possibly because ofthe limited number oftumours
analysed. The results of the present study indicate lower serum
levels of soluble ectodomain in more advanced stages and grades
ofrenal cellcarcinoma. Whetherthis is because oflowerproduction,
diminished shedding or possibly an increased metabolism of the
oncoprotein fragment is uncertain.
The c-erbB-2 oncoprotein expression has previously been
studied in a limited number of renal cell carcinomas. Herrera
(1991), in an analysis on cystic renal disease using immunohisto-
chemistry on formalin-fixed paraffin-embedded material, found
overexpression of the c-erbB-2 oncoprotein in two out of five
renal cell carcinomas. No correlation with disease stage or tumour
grade was presented. Stumm et al (1996) found high levels of
c-erbB-2 oncoprotein expression in 64% of fresh-frozen tumours
using immunohistochemistry, but the relation to stage and grade
was uncertain. In the present study, an inverse relation between
tumour grade, disease stage, survival time and the serum level of
c-erbB-2 oncoprotein was observed. Our results are in line with
previous studies in colonic and ovarian cancer. Cohen et al (1989),
using cell lines from colonic cancers, found lower c-erbB-2
expression in poorly differentiated tumours than in more differen-
tiated tumours. McKenzie et al (1993) analysed soluble
ectodomain of c-erbB-2 oncoprotein in ovarian cancer and found
significantly lower levels in more advanced disease stages and a
tendency towards lower levels in poorly differentiated tumours. In
breast cancer, the c-erbB-2 oncogene expression was increased in
more advanced disease stages and in poorly differentiated tumours
(Slamon etal, 1987; Lupu et al, 1995), findings that are opposed to
the results of the present study. Variable results have been
presented in other studies ofbreast cancerin which expression was
found to be at a higher frequency in ductal carcinoma in situ
tumours than in invasive tumours (van de Vijveret al, 1988; Allred
et al, 1992).
Univariate analysis of the prognostic value of the soluble
ectodomain of c-erbB-2 in the present study shows that the level
was inversely related to survival time. This result is opposed to the
findings in breast cancer, in which overexpression of c-erbB-2
oncoprotein is a negative prognostic factor (Slamon et al, 1987;
Tandon et al, 1989; Kandl et al, 1994). When prognosis was evalu-
ated in a multivariate analysis in renal cell carcinoma, the strong
predictors were stage and grade in accordance with earlier reports
(Thrasher and Paulson, 1993), while c-erbB-2 oncoprotein lost its
independent prognostic value.
In conclusion, an inverse relation between serum levels of the
soluble ectodomain of c-erbB-2 oncoprotein and disease stage,
tumour grade and survival time in renal cell carcinoma was found.
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